Magnitude and Frequency of Cytotoxic T-Lymphocyte Responses: Identification of Immunodominant Regions of Human Immunodeficiency Virus Type 1 Subtype C

ABSTRACT A systematic analysis of immune responses on a population level is critical for a human immunodeficiency virus type 1 (HIV-1) vaccine design. Our studies in Botswana on (i) molecular analysis of the HIV-1 subtype C (HIV-1C) epidemic, (ii) frequencies of major histocompatibility complex class I HLA types, and (iii) cytotoxic T-lymphocyte (CTL) responses in the course of natural infection allowed us to address HIV-1C-specific immune responses on a population level. We analyzed the magnitude and frequency of the gamma interferon ELISPOT-based CTL responses and translated them into normalized cumulative CTL responses. The introduction of population-based cumulative CTL responses reflected both (i) essentials of the predominant virus circulating locally in Botswana and (ii) specificities of the genetic background of the Botswana population, and it allowed the identification of immunodominant regions across the entire HIV-1C. The most robust and vigorous immune responses were found within the HIV-1C proteins Gag p24, Vpr, Tat, and Nef. In addition, moderately strong responses were scattered across Gag p24, Pol reverse transcriptase and integrase, Vif, Tat, Env gp120 and gp41, and Nef. Assuming that at least some of the immune responses are protective, these identified immunodominant regions could be utilized in designing an HIV vaccine candidate for the population of southern Africa. Targeting multiple immunodominant regions should improve the overall vaccine immunogenicity in the local population and minimize viral escape from immune recognition. Furthermore, the analysis of HIV-1C-specific immune responses on a population level represents a comprehensive systematic approach in HIV vaccine design and should be considered for other HIV-1 subtypes and/or different geographic areas.

[1]  F. Graham,et al.  Immunogenicity in mice of tandem repeats of an epitope from herpes simplex gD protein when expressed by recombinant adenovirus vectors. , 1993, Vaccine.

[2]  D. Hone,et al.  Vaccination with a Shigella DNA Vaccine Vector Induces Antigen-Specific CD8+ T Cells and Antiviral Protective Immunity , 2001, Journal of Virology.

[3]  Y. Okamoto,et al.  Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[4]  H. Sheppard,et al.  Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection. , 1998, AIDS research and human retroviruses.

[5]  Gilcher Ro Human retroviruses and AIDS. , 1988 .

[6]  Neff Walker,et al.  Estimated Global Distribution and Regional Spread of HIV‐1 Genetic Subtypes in the Year 2000 , 2002, Journal of acquired immune deficiency syndromes.

[7]  P. Kaleebu,et al.  Cross‐clade recognition of p55 by cytotoxic T lymphocytes in HIV‐1 infection , 1998, AIDS.

[8]  A. McMichael,et al.  Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. , 1999, Vaccine.

[9]  F. Vannberg,et al.  Human Immunodeficiency Virus Type 1 Subtype C Molecular Phylogeny: Consensus Sequence for an AIDS Vaccine Design? , 2002, Journal of Virology.

[10]  B. Walker,et al.  Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development , 1997, Journal of virology.

[11]  D. Simmons,et al.  Functional analysis of amino acid residues encompassing and surrounding two neighboring H-2Db-restricted cytotoxic T-lymphocyte epitopes in simian virus 40 tumor antigen , 1995, Journal of virology.

[12]  B. Moss,et al.  Reduction of Simian-Human Immunodeficiency Virus 89.6P Viremia in Rhesus Monkeys by Recombinant Modified Vaccinia Virus Ankara Vaccination , 2001, Journal of Virology.

[13]  E. Wherry,et al.  The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. , 1999, Journal of immunology.

[14]  W. Fawzi,et al.  Differences in perinatal transmission among human immunodeficiency virus type 1 genotypes. , 2001, Journal of human virology.

[15]  B. Moss,et al.  Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[17]  M. Reitz,et al.  Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector. , 2001, Vaccine.

[18]  Y. Paterson,et al.  Th1 T cell responses to HIV-1 Gag protein delivered by a Listeria monocytogenes vaccine are similar to those induced by endogenous listerial antigens. , 1999, Journal of immunology.

[19]  B. Guy,et al.  Gag-specific cytotoxic T lymphocytes from human immunodeficiency virus type 1-infected individuals: Gag epitopes are clustered in three regions of the p24gag protein , 1993, Journal of virology.

[20]  E. Rosenberg,et al.  Differential Narrow Focusing of Immunodominant Human Immunodeficiency Virus Gag-Specific Cytotoxic T-Lymphocyte Responses in Infected African and Caucasoid Adults and Children , 2000, Journal of Virology.

[21]  J. Yewdell,et al.  Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. , 1999, Annual review of immunology.

[22]  A. McMichael,et al.  Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. , 2000, Nature Medicine.

[23]  N. Shastri,et al.  Presentation of endogenous peptide/MHC class I complexes is profoundly influenced by specific C-terminal flanking residues. , 1995, Journal of immunology.

[24]  B. Graham Clinical trials of HIV vaccines. , 2002, Annual review of medicine.

[25]  Brian T. Foley,et al.  HIV Sequence Compendium 2018 , 2010 .

[26]  J. Frelinger,et al.  Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians , 1997, Journal of virology.

[27]  S. Rowland-Jones,et al.  Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. , 1998, The Journal of clinical investigation.

[28]  T. F. Rinke de Wit,et al.  HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. , 1999, AIDS.

[29]  K. Cease,et al.  New insights and approaches regarding B- and T-cell epitopes in HIV vaccine design. , 1999, AIDS.

[30]  Steven M. Wolinsky,et al.  Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes , 2002, Nature.

[31]  T. Ndung’u,et al.  Construction and Analysis of an Infectious Human Immunodeficiency Virus Type 1 Subtype C Molecular Clone , 2001, Journal of Virology.

[32]  B. Moss,et al.  Elicitation of High-Frequency Cytotoxic T-Lymphocyte Responses against both Dominant and Subdominant Simian-Human Immunodeficiency Virus Epitopes by DNA Vaccination of Rhesus Monkeys , 2001, Journal of Virology.

[33]  A. Hughes,et al.  Natural selection on the gag, pol, and env genes of human immunodeficiency virus 1 (HIV-1). , 1995, Molecular biology and evolution.

[34]  J. Blackard,et al.  Increased promoter diversity reveals a complex phylogeny of human immunodeficiency virus type 1 subtype C in India. , 2000, Journal of human virology.

[35]  B. Moss,et al.  Immunization with a Modified Vaccinia Virus Expressing Simian Immunodeficiency Virus (SIV) Gag-Pol Primes for an Anamnestic Gag-Specific Cytotoxic T-Lymphocyte Response and Is Associated with Reduction of Viremia after SIV Challenge , 2000, Journal of Virology.

[36]  B. Walker,et al.  Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: relevance to HIV-1 vaccine trials in Uganda. , 2000, The Journal of infectious diseases.

[37]  J. Albert,et al.  Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. , 1999, AIDS research and human retroviruses.

[38]  S. Rowland-Jones,et al.  Distinct Recognition of Non-Clade B Human Immunodeficiency Virus Type 1 Epitopes by Cytotoxic T Lymphocytes Generated from Donors Infected in Africa , 1999, Journal of Virology.

[39]  J. Heeney,et al.  AIDS vaccine development in primate models. , 1998, AIDS.

[40]  Todd M. Allen,et al.  Induction of AIDS Virus-Specific CTL Activity in Fresh, Unstimulated Peripheral Blood Lymphocytes from Rhesus Macaques Vaccinated with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen1 , 2000, The Journal of Immunology.

[41]  B. Gicquel,et al.  Recombinant Mycobacterium bovis BCG producing the N-terminal half of SIVmac251 Env antigen induces neutralizing antibodies and cytotoxic T lymphocyte responses in mice and guinea pigs. , 1997, AIDS research and human retroviruses.

[42]  Henryk Mach,et al.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity , 2002, Nature.

[43]  Philip J. R. Goulder,et al.  PeptGen: Designing Peptides for Immunological Studies and Application to HIV Consensus Sequences , 2000 .

[44]  T. Ndung’u,et al.  Molecular cloning and biological characterization of full-length HIV-1 subtype C from Botswana. , 2000, Virology.

[45]  I. M. Belyakov,et al.  Rabies Virus-Based Vectors Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Protein Induce a Strong, Cross-Reactive Cytotoxic T-Lymphocyte Response against Envelope Proteins from Different HIV-1 Isolates , 2001, Journal of Virology.

[46]  G. Pozzi,et al.  Vaginal immunization of Cynomolgus monkeys with Streptococcus gordonii expressing HIV-1 and HPV 16 antigens. , 1998, Vaccine.

[47]  James G. Herndon,et al.  Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine , 2001, Science.

[48]  J. Berzofsky,et al.  Induction of a Mucosal Cytotoxic T-Lymphocyte Response by Intrarectal Immunization with a Replication-Deficient Recombinant Vaccinia Virus Expressing Human Immunodeficiency Virus 89.6 Envelope Protein , 1998, Journal of Virology.

[49]  Winston A Hide,et al.  Conserved domains of subtype C nef from South African HIV type 1-infected individuals include cytotoxic T lymphocyte epitope-rich regions. , 2001, AIDS research and human retroviruses.

[50]  P. Sharp,et al.  A Comprehensive Panel of Near-Full-Length Clones and Reference Sequences for Non-Subtype B Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[51]  Alessandro Sette,et al.  Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia , 2000, Nature.

[52]  A. Simon,et al.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. , 2000, Science.

[53]  A. Hughes,et al.  Conservation of cytotoxic T lymphocyte (CTL) epitopes as a host strategy to constrain parasite adaptation: evidence from the nef gene of human immunodeficiency virus 1 (HIV-1). , 1998, Molecular biology and evolution.

[54]  E. Rosenberg,et al.  Rapid Definition of Five Novel HLA-A∗3002-Restricted Human Immunodeficiency Virus-Specific Cytotoxic T-Lymphocyte Epitopes by Elispot and Intracellular Cytokine Staining Assays , 2001, Journal of Virology.

[55]  J. Berzofsky Immunodominance in T lymphocyte recognition. , 1988, Immunology letters.

[56]  J. Carr,et al.  Characterization of full-length HIV type 1 subtype C sequences from South Africa. , 2001, AIDS research and human retroviruses.

[57]  D. Montefiori,et al.  ALVAC-SIV-gag-pol-env-Based Vaccination and Macaque Major Histocompatibility Complex Class I (A*01) Delay Simian Immunodeficiency Virus SIVmac-Induced Immunodeficiency , 2002, Journal of Virology.

[58]  R. Zinkernagel,et al.  Hierarchies of antigen‐specific cytotoxic T‐cell responses , 1998, Immunological reviews.

[59]  C Crimi,et al.  Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. , 2001, Vaccine.

[60]  J. Esparza,et al.  Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? , 2000, The Lancet.

[61]  G. Dougan,et al.  Construction, expression, and immunogenicity of multiple tandem copies of the Schistosoma mansoni peptide 115-131 of the P28 glutathione S-transferase expressed as C-terminal fusions to tetanus toxin fragment C in a live aro-attenuated vaccine strain of Salmonella. , 1994, Journal of immunology.

[62]  R. Young,et al.  Humoral and cell-mediated immune responses to live recombinant BCG–HIV vaccines , 1991, Nature.

[63]  P. Flores-Villanueva,et al.  Identification of most frequent HLA class I antigen specificities in Botswana: relevance for HIV vaccine design. , 2001, Human immunology.

[64]  K. Cease,et al.  A V3 loop haptenic peptide sequence, when tandemly repeated, enhances immunogenicity by facilitating helper T-cell responses to a covalently linked carrier protein. , 1999, Vaccine.

[65]  Edward C. Holmes,et al.  Clustered Mutations in HIV-1 Gag Are Consistently Required for Escape from Hla-B27–Restricted Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.

[66]  F. Vannberg,et al.  Identification of Human Immunodeficiency Virus Type 1 Subtype C Gag-, Tat-, Rev-, and Nef-Specific Elispot-Based Cytotoxic T-Lymphocyte Responses for AIDS Vaccine Design , 2001 .

[67]  J. Mcghee,et al.  Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses. , 1996, Journal of biotechnology.

[68]  M. Robert-Guroff,et al.  Deletion of N-terminal myristoylation site of HIV Nef abrogates both MHC-1 and CD4 down-regulation. , 2001, Immunology letters.

[69]  E. Rosenberg,et al.  The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[70]  B. Gicquel,et al.  Oral immunization with recombinant Mycobacterium bovis BCG simian immunodeficiency virus nef induces local and systemic cytotoxic T-lymphocyte responses in mice , 1997, Journal of virology.

[71]  H. Eisen,et al.  Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses. , 1995, Journal of immunology.

[72]  M. L. Clements-Mann,et al.  A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. , 1999, The Journal of infectious diseases.

[73]  Todd M. Allen,et al.  Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef , 1999, Nature Medicine.

[74]  J. Lieberman,et al.  Induction of Human Immunodeficiency Virus (HIV)-Specific CD8 T-Cell Responses by Listeria monocytogenes and a Hyperattenuated Listeria Strain Engineered To Express HIV Antigens , 2000, Journal of Virology.

[75]  J. Morvan,et al.  Cross-Reactions between the Cytotoxic T-Lymphocyte Responses of Human Immunodeficiency Virus-Infected African and European Patients , 1998, Journal of Virology.

[76]  E. Rosenberg,et al.  Important contribution of p15 Gag-specific responses to the total Gag-specific CTL responses , 2002, AIDS.

[77]  A. García-Sastre,et al.  Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants. , 1999, Vaccine.

[78]  B. Gicquel,et al.  A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes. , 1998, AIDS research and human retroviruses.

[79]  N. Nathanson,et al.  The role of nonhuman primates in the development of an AIDS vaccine. , 1999, AIDS.

[80]  P. Earl,et al.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. , 2002, Vaccine.

[81]  M. Johnston,et al.  The role of nonhuman primate models in AIDS vaccine development. , 2000, Molecular medicine today.

[82]  C. Ho,et al.  Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes. , 1996, Journal of immunology.

[83]  D. Gotte,et al.  Full-length sequence of an ethiopian human immunodeficiency virus type 1 (HIV-1) isolate of genetic subtype C. , 1996, AIDS research and human retroviruses.

[84]  F. Frankel,et al.  Systemic Immunity and Mucosal Immunity Are Induced against Human Immunodeficiency Virus Gag Protein in Mice by a New Hyperattenuated Strain of Listeria monocytogenes , 2001, Journal of Virology.

[85]  C. DeLisi,et al.  The organization of human leucocyte antigen class I epitopes in HIV genome products: implications for HIV evolution and vaccine design. , 1997, Vaccine.

[86]  A. Craiu,et al.  Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[87]  J. Albert,et al.  Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. , 1998, Virology.

[88]  J. Levy,et al.  Identification of multirestricted immunodominant regions recognized by cytolytic T lymphocytes in the human immunodeficiency virus type 1 Nef protein , 1995, Journal of virology.

[89]  M. Zazzi,et al.  Antigenicity and immunogenicity of the V3 domain of HIV type 1 glycoprotein 120 expressed on the surface of Streptococcus gordonii. , 1999, AIDS research and human retroviruses.

[90]  D. Robertson,et al.  Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. , 2001, AIDS research and human retroviruses.

[91]  A. Iwasaki,et al.  Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. , 1997, Journal of immunology.

[92]  M. Hofnung,et al.  Induction of T cell responses by chimeric bacterial proteins expressing several copies of a viral T cell epitope , 1993, European journal of immunology.

[93]  M. Peeters,et al.  Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[94]  P. Biberfeld,et al.  Recombinant Semliki Forest virus vaccine vectors: the route of injection determines the localization of vector RNA and subsequent T cell response , 2001, Gene Therapy.

[95]  B. Walker,et al.  HIV Molecular Immunology 2001 , 2001 .

[96]  F. Vannberg,et al.  Molecular Cloning and Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Subtype C: a Set of 23 Full-Length Clones from Botswana , 1999, Journal of Virology.

[97]  Forest M. White,et al.  Immunodominance Among EBV-Derived Epitopes Restricted by HLA-B27 Does Not Correlate with Epitope Abundance in EBV-Transformed B-Lymphoblastoid Cell Lines1 , 2000, The Journal of Immunology.

[98]  E. Rosenberg,et al.  Vpr Is Preferentially Targeted by CTL During HIV-1 Infection1 , 2001, The Journal of Immunology.

[99]  J. Neilson,et al.  Subtypes of Human Immunodeficiency Virus Type 1 and Disease Stage among Women in Nairobi, Kenya , 1999, Journal of Virology.